Jennifer Kayden Lee
Insider (Form 4 reporting owner): EVP, Head of North America CIK 1801372Name as filed: Lee Jennifer KaydenIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 15 Feb 2022, sold $16.9M in 19 sales (11 under a 10b5-1 plan set in advance) of Rhythm Pharmaceuticals.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals RYTM | EVP, Head of North America | 15 Feb 2022 | 13 Aug 2026 | – | 19$16.9M |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | -1.7 pts10 trades, 50% above the sector | +31.1 pts9 trades, 78% above the sector | +65.9 pts9 trades, 100% above the sector |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 1 | $8.9M | -$8.9M |
| 2025 | – | – | 5 | $866K | -$866K |
| 2024 | – | – | 5 | $5.9M | -$5.9M |
| 2023 | – | – | 7 | $1.2M | -$1.2M |
| 2022 | – | – | 1 | $4K | -$4K |
Every trade
20, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 13 Aug 2026 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 75,834 | $117.38 | $8.9M | 10b5-1 plan | Form 4filed 14 Aug 2026 |
| 19 Feb 2025 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 2,035 | $57.22 | $116K | 10b5-1 plan | Form 4filed 19 Feb 2025 |
| 12 Feb 2025 | Rhythm Pharmaceuticals RYTM | Sell | 3,020 | $57.03 | $172K | 10b5-1 plan | Form 4filed 14 Feb 2025 |
| 10 Feb 2025 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 5,216 | $58.63 | $306K | 10b5-1 plan | Form 4filed 11 Feb 2025 |
| 5 Feb 2025 | Rhythm Pharmaceuticals RYTM | Sell | 3,066 | $60.55 | $186K | 10b5-1 plan | Form 4filed 7 Feb 2025 |
| 4 Feb 2025 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 1,447 | $59.43 | $86K | No | Form 4filed 4 Feb 2025 |
| 11 Nov 2024 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 66,861 | $66.33 | $4.4M | 10b5-1 plan | Form 4filed 13 Nov 2024 |
| 20 Mar 2024 | Rhythm Pharmaceuticals RYTM | Sell | 18,235 | $38.77 | $707K | No | Form 4filed 22 Mar 2024 |
| 19 Mar 2024 | Rhythm Pharmaceuticals RYTM | Sell | 15,515 | $39.22 | $608K | No | Form 4filed 19 Mar 2024 |
| 12 Feb 2024 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 1,638 | $50.80 | $83K | No | Form 4filed 13 Feb 2024 |
| 1 Feb 2024 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 1,492 | $45.06 | $67K | No | Form 4filed 5 Feb 2024 |
| 14 Nov 2023 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 13,677 | $32.01 | $438K | 10b5-1 plan | Form 4filed 16 Nov 2023 |
| 8 Nov 2023 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 9,150 | $28.44 | $260K | 10b5-1 plan | Form 4filed 13 Nov 2023 |
| 3 Nov 2023 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 80 | $28.00 | $2K | 10b5-1 plan | Form 4filed 7 Nov 2023 |
| 5 Sep 2023 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 6,166 | $28.05 | $173K | 10b5-1 plan | Form 4filed 7 Sep 2023 |
| 7 Aug 2023 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 12,941 | $24.24 | $314K | 10b5-1 plan | Form 4filed 9 Aug 2023 |
| 14 Feb 2023 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 635 | $26.87 | $17K | Not stated | Form 4filed 14 Feb 2023 |
| 9 Feb 2023 | Rhythm Pharmaceuticals RYTM | Sellamended filing (4/A), not counted again | 1,204 | $27.51 | $33K | Not stated | Form 4/Afiled 14 Feb 2023 |
| 9 Feb 2023 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 1,192 | $27.66 | $33K | Not stated | Form 4filed 13 Feb 2023 |
| 15 Feb 2022 | Rhythm Pharmaceuticals RYTM | Sellafter exercising options | 722 | $6.10 | $4K | Not stated | Form 4filed 15 Feb 2022 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.